The evidence is clear: vaccines are one of the most cost-effective investments in health and development in history. Gavi helps save children’s lives and protect people’s health by increasing equitable use of vaccines in lower-income countries.

More than 8 million deaths averted

Since its inception in 2000, Gavi has helped developing countries to prevent more than 8 million future deaths through its support to 10 vaccines: pentavalent, pneumococcal, rotavirus, yellow fever, meningitis A, Japanese encephalitis, HPV, measles second dose, measles-rubella and rubella.

Source: Gavi, the Vaccine Alliance/Bill & Melinda Gates Foundation 2016

Close to 580 million children immunised

Since 2000, Gavi support has contributed to the immunisation of close to 580 million children.

Source: WHO/UNICEF 2016

Reaching 81% coverage with DTP3

In 2015, coverage with three doses of diphtheria-tetanus-pertussis vaccine-containing vaccine (DTP3), including pentavalent vaccine, in Gavi-supported countries reached 81% – just 5 percentage points below the global average. This represents an increase of 21 percentage points since our foundation in 2000.

Source: WHO/UNICEF 2016

More than 65 million children immunised in 2015

In 2015 alone, more than 65 million children were immunised with Gavi-supported vaccines. This equates to over 195 million points of contact between these children and the primary health system and can provide a robust platform for other health interventions.

Source: WHO/UNICEF 2016

Health systems and immunisation services strengthened in more than 60 countries

The Vaccine Alliance has helped to strengthen health systems and immunisation services in more than 60 countries.

Source: Gavi

More than 4 million deaths averted between 2011 and 2015

The Vaccine Alliance’s support for vaccines contributed to averting more than 4 million future deaths between 2011 and 2015.

Source: Gavi, the Vaccine Alliance/Bill & Melinda Gates Foundation 2016

277 million children immunised 2011–2015

Gavi support helped countries to immunise 277 million children between 2011 and 2015.

Source: WHO/UNICEF 2016

Over 200 vaccine introductions between 2011 and 2015

Gavi supported over 200 vaccine introductions and campaigns in 2011–2015 – four times as many as in the previous five years.

Source: Gavi

Return on investment of immunisation in Gavi countries: US$ 18 for every US$ 1 spent

A study in Health Affairs covering 73 Gavi-supported countries over the 2011–2020 period shows that, for every US$ 1 spent on immunisation, US$ 18 are saved in healthcare costs, lost wages and lost productivity due to illness. If we take into account the broader benefits of people living longer, healthier lives, the return on investment rises to US$ 48 per US$ 1 spent.

Note: The study also looked at the return on investment in the world’s 94 lowest-income countries. For every dollar spent in these countries, US$ 16 are saved in healthcare costs, lost wages and lost productivity. Adding the broader benefits of immunisation, this rises to US$ 44 for every dollar invested.

Source: Ozawa S, Clark S, Portnoy A et al. Return on investment from childhood immunizations in low- and middle-income countries, 2011-20, Health Affairs 2016

Nine countries have transitioned out of Gavi support

By early 2017, nine countries – Bhutan, Guyana, Honduras, Indonesia, Kiribati, Moldova, Mongolia, Sri Lanka and Ukraine1 – had started to fully self-finance all their vaccines introduced with Gavi support.

Source: Gavi

1 Gavi’s support to the Ukraine ended before the co-financing and transition policies were implemented.

Gavi supports 12 new and underused vaccines

Pentavalent vaccine: 73 countries, 296 million children, 5 antigens

In July 2014, South Sudan became the final Gavi-supported country to introduce the five-in-one pentavalent vaccine. By the end of 2015, 296 million children had been immunised with pentavalent vaccine with Gavi support.

Source: WHO/UNICEF 2016

76 million children vaccinated against pneumococcal disease

By the end of 2015, Gavi had contributed to immunising 76 million children against pneumococcal disease. Gavi surpassed its 2015 target of 45 introductions already in 2014 – more than one year ahead of schedule. More than three-quarters of all Gavi-supported countries have introduced the vaccine.

Source: WHO/UNICEF 2016

More than 36 million children vaccinated against rotavirus

Vaccine Alliance support has contributed to immunising more than 36 million children against rotavirus diarrhoea. By the end of 2015, more than half of all Gavi-supported countries had introduced the vaccine.

Source: WHO/UNICEF 2016

235 million people immunised against meningitis A

By the end of 2015, 16 countries in the African meningitis belt had collectively immunised 235 million people against meningitis A with support from Gavi.

Source: WHO/UNICEF 2016

Meningitis A, C, Y, W combination vaccine stockpile prevents outbreaks

Gavi funds a stockpile of multivalent vaccine to prevent outbreaks of meningitis A, C, W and Y. Doses from the stockpile played a critical role in controlling the 2015 meningitis C outbreak in Niger.

Source: Gavi 2016

Human papillomavirus vaccine demonstration programmes: 1 million girls reached

Since the first human papillomavirus (HPV) vaccine demonstration programme in Kenya in 2013, 1 million girls have been immunised with Gavi support. Gavi is already supporting national HPV vaccine programmes in Honduras, Rwanda and Uganda.

Source: Gavi 2016

10 million children immunised against polio

In September 2014, Nepal became the first country to introduce inactivated polio vaccine (IPV) with Gavi support. By the end of 2015, close to 40 countries had introduced the vaccine with our support, collectively immunising 10 million children.

Source: Gavi 2016

32 million reached with measles second dose vaccine

Since 2007, countries have immunised 32 million children with a second dose of measles vaccine with Gavi support. Gavi- funded measles campaigns have helped vaccinate another 118 million children in countries at high risk of outbreaks.

Source: WHO/UNICEF 2016

Measles-rubella vaccine reaches 164 million people

By the end of 2015, Gavi-funded measles-rubella catch-up campaigns, targeting the next generation of mothers and children aged 9 months to 14 years, had reached 164 million people.

Source: WHO/UNICEF 2016

Yellow fever vaccine: mass prevention campaigns and routine immunisation

Since 2011, Gavi-supported campaigns have protected over 98 million people in 14 countries. We have also helped 17 countries introduce yellow fever vaccine through routine immunisation, immunising more than 90 million children.

Source: Gavi 2016

Oral cholera vaccine stockpile helps vaccinate more than 1 million people

Since its creation in 2013, the global oral cholera vaccine stockpile has been used to vaccinate more than 1 million people; in 2015, campaigns took place in Bangladesh, Cameroon, Haiti, Malawi, Tanzania and South Sudan.

Source: Gavi 2016

Japanese encephalitis: Lao first to introduce vaccine with Gavi support

In April 2015, Lao PDR became the first country to introduce Japanese encephalitis (JE) vaccine with Gavi support. By the end of the year, 1.6 million children aged between 9 months and 14 years had been immunised against JE.

Source: Gavi 2016

While we continue to help countries introduce new vaccines, our focus is expanding. Our task now is to reach every child with these vaccines, regardless of where they are born or how rich their families are, and whether they are boys or girls.

1.5 million children under five lose their lives to vaccine-preventable diseases every year

In 2012, approximately 6.6 million children died before the age of five. WHO estimates that 1.5 million of these deaths were due to vaccine-preventable diseases.

Source: WHO

19 million under-immunised

19 million infants remain under-immunised with three doses of DTP in the world each year. Almost one in five of all children in Gavi-supported countries miss out on a full course of this basic package of vaccines.

Source: WHO/UNICEF 2016

95% of children miss out on recommended vaccines

Over 95% of children in Gavi-supported countries do not yet have access to all 11 vaccines recommended by WHO for infants in all countries.

Source: WHO/UNICEF 2015

Focus on 20 priority countries

In the 2016–2020 period we are intensifying our efforts in 20 priority countries. Ten of these – Afghanistan, Chad, the Democratic Republic of the Congo, Ethiopia, India, Indonesia, Kenya, Nigeria, Pakistan and Uganda – account for over 70% of the underimmunised children in Gavi-supported countries, so improving their immunisation coverage is critical.

We are also prioritising an additional 10 countries, which face severe inequities or crises: the Central African Republic, Haiti, Madagascar, Mozambique, Myanmar, Niger, Papua New Guinea, Somalia, South Sudan and Yemen.

Source: WHO/UNICEF 2016

Over a quarter of child deaths are due to pneumonia and diarrhoea

Pneumonia and diarrhoea account for 26% of deaths in under-fives in Gavi-supported countries.

Source: CHERG-WHO 2014

Gender barriers can prevent children from being immunised

A 2010 study by WHO found that there is no significant difference in immunisation levels for boys and girls at the global level. Yet in some societies boys are privileged over girls. In others, the opposite is true and girls have greater access to vaccines than boys. In societies where women have low status and therefore lack access to immunisation and other health services, both girls and boys are less likely to be immunised.

Source: WHO

One woman dies every 2 minutes from cervical cancer

One woman dies from cervical cancer every two minutes – or 266,000 a year – over 85% in the developing world. If current trends hold, and without changes in prevention and control, cervical cancer deaths could eventually outpace maternal deaths. Two-thirds of all cervical cancer deaths can be prevented with HPV vaccines.

Source: WHO

90,000 born with birth defects due to rubella

Every year, 90,000 babies in Gavi countries are born with severe birth defects known as congenital rubella syndrome because their mothers were infected with rubella during pregnancy. The combined measles-rubella vaccine, which Gavi supports, can help prevent this devastating disease.

Source: WHO

Pentavalent, pneumococcal and rotavirus vaccines: 43% reduction since 2010

The total cost of fully immunising a child with pentavalent, pneumococcal and rotavirus vaccines fell by 43% from US$ 35 in 2010 to US$ 20 in 2015.

Pentavalent (DTP-hep B-Hib) vaccine: a reduction of 44% to US$ 1.68 per dose

The weighted average price of pentavalent vaccine per dose dropped from US$ 2.98 in 2010 to US$ 1.68 in 2015, and is expected to decrease further to US$ 0.79 by 2019.

Pneumococcal vaccines through the AMC: less than 10% of the US public price

Through the Advance Market Commitment (AMC), pneumococcal vaccines are available to Gavi-supported countries at no more than US$ 3.50 per dose – less than 10% of the public price in the USA. By early 2017, Gavi had secured lowest price offers from both its pneumococcal vaccine suppliers of US$ 3.05 per dose.

Rotavirus vaccine: lowest price of US$ 2.50 per dose

Thanks to long-term supply agreements with manufacturers, Gavi has negotiated a lowest price for one type of rotavirus vaccine of €1.88 per dose (approximately US$ 2.50 per dose and US$ 5 per course). This is less than 3% of the 2015 public price in the USA (US$ 91.05 per dose).

Inactivated polio vaccine: available to Gavi countries from €0.75

The inactivated polio vaccine is available to Gavi-supported countries from as little as €0.75 (approximately US$ 1) per dose. Middle-income countries are able to buy the vaccine through UNICEF for between €1.49 and €2.40 (approximately US$ 2.04–3.28) per dose.

Human papillomavirus (HPV) vaccine: two-thirds reduction to US$ 4.50

Gavi, the Vaccine Alliance works with manufacturers to bring down HPV vaccine prices. In 2013, a price of US$ 4.50 per dose for one of the vaccines was agreed, a two-thirds reduction on the previous lowest public price.

Manufacturing base grown from 5 to 16 – more than half based in Africa, Asia and Latin America

2001: 5 vaccine manufacturers producing prequalified, appropriate Gavi vaccines – 1 based in Africa

2015: 16 vaccine manufacturers producing prequalified, appropriate Gavi vaccines – 9 based in Africa, Asia and Latin America.

Sources: Gavi, the Vaccine Alliance, UNICEF Supply Division and CDC vaccine price list, 2016.

Accelerating impact

Between 2016 and 2020, Gavi will help countries to immunise another 300 million children against potentially fatal diseases, saving between 5 and 6 million lives in the long term.

Reaching more children with more vaccines

We will also help increase the percentage of children in Gavi-supported countries who are immunised with the 11 vaccines recommended by WHO for infants everywhere, from 5% to 50% by 2020.

Country co-financing to reach US$ 1 billion in 2016–2020

Co-financing is key to the long-term sustainability of immunisation programmes. Countries’ co-financing payments are expected to amount to approximately US$ 1 billion in the 2016–2020 period.

20 countries to transition out of Gavi support by the end of 2020

Gavi continues to help countries to build sustainable immunisation programmes. Nine countries have already started to fully self-finance all their vaccines introduced with Gavi funding. By the end of 2020, a total of 20 countries are expected to have transitioned out of our support.

close icon

modal window here